Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study
Danese S, Neurath M, Kopon A, Zakko S, Simmons T, Fogel R, Maccarone J, Zhan X, Usiskin K, Chitkara D (2018)
Publication Type: Conference contribution
Publication year: 2018
Journal
Book Volume: 12
Pages Range: S4-S5
DOI: 10.1093/ecco-jcc/jjx180.004
Authors with CRIS profile
Involved external institutions
Istituto Clinico Humanitas
Italy (IT)
Celgene Corporation
United States (USA) (US)
West Gastroenterology Medical Group
United States (USA) (US)
Gastromed
Poland (PL)
Clinical Research Institute of Michigan
United States (USA) (US)
University Hospitals Bristol NHS Foundation Trust
United Kingdom (GB)
Italy (IT)
Celgene Corporation
United States (USA) (US)
West Gastroenterology Medical Group
United States (USA) (US)
Gastromed
Poland (PL)
Clinical Research Institute of Michigan
United States (USA) (US)
University Hospitals Bristol NHS Foundation Trust
United Kingdom (GB)
How to cite
APA:
Danese, S., Neurath, M., Kopon, A., Zakko, S., Simmons, T., Fogel, R.,... Chitkara, D. (2018). Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study. (pp. S4-S5).
MLA:
Danese, S., et al. "Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study." 2018. S4-S5.
BibTeX: Download